What is the main cause for human
suffering and deaths worldwide? Until recently, it used to be infectious
diseases. But in the last 15 years or so, heart disease has taken the
helm, becoming responsible for a quarter of deaths each year,
There are many approaches to prevent
diseases. Among them, the use of effective vaccines is popular,
effective and desirable. Vaccination is the administration of antigenic
material to induce an individual’s immune system to develop antibodies
to a pathogen. It is a time-tested technique a and long-lasting method
to prevent infectious diseases. A vaccine against cardiovascular disease
has not been not available until now – although that may soon change.
A study published recnetly has
become the first of its kind to show that it is possible to immunise
genetically modified mice with a molecule that causes the body to
produce antibodies against PCSK9 (proprotein covertase subtilisin/kexin
type 9), an enzyme that plays a pivotal role in preventing the clearance
of low density lipoprotein (“bad”) cholesterol from the blood.
This enzyme binds to the low-density
lipoprotein receptor and enhances its degradation. This leads to the
reduced clearance of low-density lipoprotein (LDL) and a higher risk of
atherosclerosis, a disease in which plaque builds up inside the
arteries.
In the present study, researchers
evaluated a vaccine, dubbed AT04A
anti-PCSK9, for its therapeutic potential to ameliorate or even prevent
coronary heart disease in the APOE*3Leiden.CETP mouse model. These are
genetically modified mice for human-like lipid metabolism.
Their response to lipid-lowering and high-density lipoprotein increasing
interventions is similar to that of humans.
Impressive results in mice
According to a press release , “At present, drugs such as statins can be used
to lower LDL cholesterol, but they have to be taken on a daily basis and
although they are generally well-tolerated they can cause adverse side
effects in some people. The most recently approved cholesterol-lowering
compounds are monoclonal antibodies targeting PCSK9, which are highly
effective, but their effect is short-lived, resulting in frequent
reapplication and high costs.”
Researchers fed the vaccine-treated
mice with a fatty Western diet for 18 weeks. They then monitored the
antibody titres, plasma lipids and inflammatory markers by advanced,
analytical procedures. They found that AT04A vaccine induces an
effective immune response against PCSK9 in APOE*3Leiden.CETP mice,
leading to a significant reduction of plasma lipids, systemic and
vascular inflammation and atherosclerotic lesions in the aorta, the main
artery.
They concluded that the vaccine might
represent an effective approach for the treatment and even prevention
of cardiovascular disease. But will it also be economic, as they claim? There
is little doubt that the cost of the vaccine is bound to be prohibitive
to the many who will need it. For example, a treatment regimen
involving either alirocumab and evolocumab, both inhibitors of the PCSK9
enzyme, has been estimated to cost very high, which most patients won't be able to afford.
Nonetheless, the results of using the
vaccine were very impressive. Also according to the release, “The AT04A
vaccine, when injected under the skin in mice … reduced the total
amount of cholesterol by 53%, shrank atherosclerotic damage to blood
vessels by 64% and reduced biological markers of blood vessel
inflammation by 21-28%, compared to unvaccinated mice.” It added that
the antibodies introduced by the vaccine had “remained functional over
the whole study period” and that “concentrations were still high at the
end of the study.”
“If these findings translate
successfully into humans, this could mean that, as the induced
antibodies persist for months after a vaccination, we could develop a
long-lasting therapy that, after the first vaccination, just needs an
annual booster,” the release quotes one of the study’s
authors
as saying. “This would result in an effective and more convenient
treatment for patients, as well as higher patient compliance.”
He also told this correspondent
that that they were currently performing a phase-one clinical trial to
immunise people, and that the final results will become available in
early 2018.
Potential side effects
He explained, “The way that AT04A is
administered is comparable to a vaccine. However, the difference between
a conventional vaccine and our approach is that a vaccine induces
antibodies that are specific to bacterial or viral proteins that are
foreign to the body – pathogens – whereas AT04A induces antibodies
against a target protein that is produced by the body: endogenous proteins. Thus it is really an immunotherapeutic approach rather than a vaccine approach.”
He clarified that they hope to sell their drug commercially by 2023-2025 depending on the market and the geography.
Will potential side effects of the
vaccine, such as type 2 diabetes, have to be considered before
submitting the vaccine for approval? “Although it has been published that LDL lowering by
either statins or PCSK9 blockers might be associated with a small
increased risk in new-onset of diabetes, the impact of these drugs on
glycemic control parameters in patients with diabetes mellitus still
remains unclear,” he answered. “However, upcoming clinical studies
using AT04 have to prove safety of this immunotherapeutic drug also in
terms of new-onset of diabetes.”
The phase one trial underway with
humans – which he mentioned earlier – commenced in 2015. In
the trial, AT04A and another molecule, AT06A, were given to 72 healthy
people to assess their safety and activity.
A professor of clinical
and experimental medicine and an associate professor of medicine wrote in an editorial accompanying the mice study that the
results appeared “promising”. However, they cautioned, “Safety, the
response in humans and the very important but unknown long-term immune
effects need to be very carefully addressed during the course of
clinical development.”
They also noted that reductions in
total cholesterol via statins and other drugs have been associated with
an increase in new onset diabetes. “Therefore, potential safety concern
for long-term lowering of LDL cholesterol with a vaccine directed
against PCSK9 is the potential for an increased risk of new onset
diabetes. In the short term, the LDL cholesterol lowering effect of
statins and PCS9 inhibitors appears to far outweigh the risks of new
onset diabetes,” they concluded.
this is only for your
information, kindly take the advice of your doctor for medicines,
exercises and so on.
https://gscrochetdesigns.blogspot.com. one can see my crochet creations https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement
Labels: Cholesterol, heart diseases, lowering, Protect, statins, type 2 diabetes, vaccines